OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...

Explore OS Therapies stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for OSTX. Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer ...

Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical ...

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are ...

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and ...

OS Therapies (OSTX) announced that it has scheduled a Scientific Advice Meeting in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway with the United Kingdom’s ...